Patent EA-000768-B1 (EA)
Title: Method for treating autism
Inventor: BEASLEY CHARLES M
IPC: A61P25/28
Filed: 1996-12-04
Abstract: 1. A method for treating Autistic Disorder comprising administering to a mammal in need of such treatment, an effective mount of olanzapine, or a pharmaceutically acceptable salt or solvate thereof. 2. A method of claim 1 wherein the Autistic Disorder is classified as a DSM-IV-R category selected from the group consisting of 299.0, 299.80, and 299.10. 3. A method of claim 2 wherein the Autiscic Disorder is classified as DSM-IV-R category 299.0. 4. A method of claim 1 wherein olanzapine is Form II olanzapine polymorph having a typical x-ray diffraction pattern as follows, wherein d represents the interplanar spacing: d 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007 5. A method of claim 2 wherein olanzapine is Form II olanzapine polymorph having a typical x-ray diffraction pattern as follows, wherein d represents the interplanar spacing: d 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007 6. A method of claim 1 wherein the effective amount is from about 1 mg to about 25 mg per day. 7. A method of claim 4 wherein the effective amount is from about 1 mg to about 30 mg per day. 8. A method for treating Mental Retardation comprising administering to a mammal in need of such treatment, an effective amount of olanzapine, or a pharmaceutically acceptable salt or solvate thereof. 9. A method of claim 8 wherein the Mental Retardation is classified as a DSM-IV-R category selected from the group consisting of 317, 318.0, 318.1, 318.2, and 319. 10. A method of claim 9 wherein the Mental Retardation is selected from the group consisting of 318.0, 318.1, and 318.2. 11. A method of claim 8 wherein olanzapine is Form II olanzapine polymorph having a typical x-ray diffraction pattern as follows, wherein d represents the interplanar spacing: d 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.134 3.0848 3.2516 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007 12. A method of claim 8 wherein the effective amount is from about 1 mg to about 25 mg per day. 13. A method of claim 11 wherein the effective amount is from about 1 ing to about 30 mg per day. 14. A use of olanzapine or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for therapeutic use in the treatment of Autistic Disorder. 15. A use of olanzapine or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for therapeutic use in the treatment of Mental Retardation. 16. A use as claimed by any one of claims 14 or 15 wherein olanzapine is Form II olanzapine polymorph having a typical x-ray diffraction pattern as follows, wherein d represents the interplanar spacing: d 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007